Compassionate use of ruxolitinib for serious conditions
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This program lets people with serious or life-threatening conditions get access to a medicine called ruxolitinib when they have no other good options and cannot join a clinical trial. It is a special access or compassionate use program, so your doctor must request it for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your own doctor must ask the drug company for this medicine for you.
- You have a serious or life-threatening illness and no other good treatment options.
- You cannot join a clinical trial or stay in one.
- Your doctor believes the possible benefits of this medicine outweigh the risks for you.
- The medicine will not get in the way of ongoing research, and your country allows this kind of special access.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests ruxolitinib (a targeted medicine) in people with essential thrombocythemia or polycythemia vera who still have troublesome symptoms. It aims to see whether it can reduce symptoms by changing disease activity and blood-related inflammation.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This trial gives people with serious diseases access to a special cell therapy (a treatment made from your own immune cells) when they have no other options. It's a 'compassionate use' program, meaning the drug is available outside of a clinical trial if you meet certain conditions.
This trial studies ruxolitinib, a medicine that affects immune signaling, in people whose T-cell or NK-cell lymphoma has returned or hasn’t responded to treatment. It may help shrink lymphoma and improve symptoms after other therapies.
This trial tests a drug called ruxolitinib for a rare but serious condition called IEC-HS that can happen after CAR T cell treatment. The goal is to see if ruxolitinib can calm this overactive immune response.
This trial tests whether taking the drug ruxolitinib before, during, and after a stem cell transplant helps older patients with myelofibrosis or certain related blood disorders. The goal is to see if this approach can improve transplant success and reduce side effects.
Hear when a new Primary Myelofibrosis (PMF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.